Bayer: new results ahead for finerenone
(CercleFinance.com) - Bayer announced on Monday that it plans to unveil new Phase III results on finerenone in heart failure at the end of the week, at the annual congress of the European Society of Cardiology (ESC).
During one of the conference's "Hot Line" sessions on Sunday, the pharmaceutical group plans to present the findings of its "Finearts-HF" clinical trial on finerenone, which involved some 6,000 patients over a 42-month period.
It aims to assess the efficacy and safety of the compound compared with placebo in patients with symptomatic heart failure with preserved left ventricular ejection fraction, i.e. greater than or equal to 40%.
Finerenone is a selective non-steroidal mineralcorticoid receptor (MR) antagonist, which blocks many of the harmful effects associated with MR over-activation that underlie the inflammatory and fibrotic processes associated with heart damage.
Earlier this month, Bayer announced that finerenone had met its primary endpoint in the trial.
In a separate 'Hot Line' session, the company plans to present the results of another phase III study of asundexian in comparison with apixaban, an oral anticoagulant, in the prevention of stroke due to atrial fibrillation.
Bayer says that heart failure is currently one of its main areas of development in cardiology.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
During one of the conference's "Hot Line" sessions on Sunday, the pharmaceutical group plans to present the findings of its "Finearts-HF" clinical trial on finerenone, which involved some 6,000 patients over a 42-month period.
It aims to assess the efficacy and safety of the compound compared with placebo in patients with symptomatic heart failure with preserved left ventricular ejection fraction, i.e. greater than or equal to 40%.
Finerenone is a selective non-steroidal mineralcorticoid receptor (MR) antagonist, which blocks many of the harmful effects associated with MR over-activation that underlie the inflammatory and fibrotic processes associated with heart damage.
Earlier this month, Bayer announced that finerenone had met its primary endpoint in the trial.
In a separate 'Hot Line' session, the company plans to present the results of another phase III study of asundexian in comparison with apixaban, an oral anticoagulant, in the prevention of stroke due to atrial fibrillation.
Bayer says that heart failure is currently one of its main areas of development in cardiology.
Copyright (c) 2024 CercleFinance.com. All rights reserved.